Endocrinology, Diabetes & Metabolism Doctors in Concord, MA Accepting Medicare

2 Endocrinology, Diabetes & Metabolism doctors found. Showing 1 - 2

Dr. William Judson Burtis, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 747 Main St, Suite 123, Concord, MA 01742 Phone: 978-287-9590    Fax: 978-287-5700

Aldona Finkle, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: May Accept Medicare Assignments Practice Location: 54 Baker Avenue Ext, Suite 301, Concord, MA 01742 Phone: 978-369-3317    Fax: 978-369-3346

News Archive

UL, MasterControl sign collaborative agreement to support medical industry

Today, UL LLC, a global safety science organization, and MasterControl, a leading global provider of electronic quality management systems (EQMS) and quality consulting services, announce a collaborative agreement which will leverage the strengths of both organizations to support the medical industry with both quality system implementation and comprehensive advice and guidance for successful global regulatory submissions.

Roundup: Cancer drug cost equity bill sitting on Calif. Gov's desk; Mass. cost-containment law could harm provider credit ratings

Out-of-pocket costs for cancer drugs can vary dramatically depending on whether the medications are administered through pill form or intravenous infusion. Newer oral drugs, which can be taken at home and often have fewer side effects than older drugs, can cost patients thousands of dollars a month, while receiving chemotherapy through an IV in an infusion center typically amounts to a standard co-payment for an office visit.

Omega Protein fourth quarter revenues increase 46% to $62.8M

Omega Protein Corporation, a nutritional ingredient company and the nation's leading vertically integrated producer of omega-3 fish oil and specialty fish meal products, today reported financial results for the fourth quarter and full year ended December 31, 2011.

PTC Therapeutics closes $150 million of convertible senior notes

PTC Therapeutics, Inc. announced today the closing of its previously announced private offering of $150 million in aggregate principal amount of its convertible senior notes due 2022 (the "Notes"), including the full exercise by the initial purchasers of an option to purchase an additional $25 million in aggregate principal amount of the Notes.

Read more Medical News

› Verified 3 days ago